CN101229183B - Ribonucleic acid retrogradation snippet compound and applications thereof - Google Patents
Ribonucleic acid retrogradation snippet compound and applications thereof Download PDFInfo
- Publication number
- CN101229183B CN101229183B CN2008100563612A CN200810056361A CN101229183B CN 101229183 B CN101229183 B CN 101229183B CN 2008100563612 A CN2008100563612 A CN 2008100563612A CN 200810056361 A CN200810056361 A CN 200810056361A CN 101229183 B CN101229183 B CN 101229183B
- Authority
- CN
- China
- Prior art keywords
- ribonucleic acid
- complex
- retrogradation
- snippet
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a degradation fragment composite of ribonucleic acid, consisting of a plurality of artificial degradation fragments of ribonucleic acid separated and purified from bowels of pigs. The quantity of nucleotide in the artificial degradation fragment of ribonucleic acid ranges from 10 to 300 and the molecular weight ranges from 2*10<2> to 6*10<4>. The invention also relates tothe application of the degradation fragment composite of ribonucleic acid in preparation of the medicine for treating polygenic diseases such as liver cancer.
Description
Technical field
The present invention relates to a kind of nucleolysis segment complex, particularly a kind of ribonucleic acid (RNA) retrogradation snippet compound and application thereof.
Background technology
Multigenic disease is the disease that is caused by the several genes pathological changes, and common have a tumor, hypertension, diabetes, acquired immune deficiency syndrome (AIDS) and old and feeble or the like, and these diseases often do not have specific drug, are difficult for curing.
Since two thousand two, microRNA be it is found that gradually for the inhibitory action of various diseases and is paid attention to.There are some researches prove that microRNA has effective inhibitory action to tumor, hepatitis C virus etc., for these treatments of perplexing human diseases provide brand-brand-new way.
The present invention is under above-mentioned technical background, use up-to-date molecular biology theory and technology, the effective ribonucleic acid retrogradation snippet compound of a kind of treatment to multiple multigenic disease has been proposed, and the application of this complex in the preparation of treatment multigenic disease medicine, in the hope of obtaining better therapeutic effect.
Summary of the invention
An object of the present invention is to provide a kind of ribonucleic acid retrogradation snippet compound, make it have effective inhibitory action, and have better effect a greater variety of multigenic diseases.
This purpose of the present invention is achieved through the following technical solutions:
A kind of ribonucleic acid retrogradation snippet compound is provided, and the artificial degraded segment of the ribonucleic acid that it is gone out by separation and purification in the haslet is formed.
The preferred non-adult pig of described pig, further preferred tire pig, the tire pig of the no chaeta of further preferred 15～20 centimeters length again.
Liver, kidney and the heart of the preferred pig of described haslet.
The method of described separation and purification can be conventional phenol extraction-sedimentation method and polyethylene glycol precipitation.Concrete grammar can be respectively:
A. phenol extraction-sedimentation method
1. the aqueous phase that contains nucleic acid that centrifugalize goes out after lysis adds isopyknic extracting solution (phenol that the 0.01M Tris balance of pH6.0 is crossed: chloroform: the volume ratio of isoamyl alcohol is 1: 1: 1/24 a mixed liquor) vibration and extracted 5～15 minutes, then 5 ℃ following 6000 rev/mins centrifugal 20 minutes, collect supernatant;
2. in step 1 gained supernatant, add isopyknic said extracted liquid, repeat said extracted and centrifugal process, collect supernatant;
3. with isopyknic chloroform step 2 gained supernatant is extracted, and 5 ℃ following 6000 rev/mins centrifugal 20 minutes, get extraction and centrifugal process that supernatant repeats this step again, collect supernatant;
4. add 95% the ethanol of 2.5 times of volumes and the 3M sodium acetate of 1/10 volume in the supernatant that step 3 obtains, precipitation is spent the night, and 5 ℃ following 6000 rev/mins collecting precipitations after centrifugal 20 minutes, precipitation is dissolved in the Tris buffer of 0.01M of pH6.0 standby;
B. polyethylene glycol precipitation
Polyethylene Glycol (PEG 4000) precipitation 30～60 minutes that in the buffer that is dissolved with impure RNA, adds equal-volume 10%, 5 ℃ following 6000 rev/mins collecting precipitations after centrifugal 20 minutes.
The method of described artificial degraded can be conventional alkaline degradation method, also can be preferably as follows method: in the buffer that is dissolved with the RNA molecule, add equal-volume 0.2N NaOH, regulate pH to 6.0 after 20～60 minutes in 0 ℃ of placement, again centrifugal 20 minutes of 5 ℃ of speed with 6000 rev/mins, collecting precipitation.Wherein regulating pH can be with 36% acetic acid solution.
The process of above-mentioned separation and purification and artificial degraded can be that with its artificial degraded, the reuse polyethylene glycol precipitation is further purified after extracting the purifying RNA macromole with phenol extraction-sedimentation method earlier; Also can be earlier with manually degraded again after phenol extraction-sedimentation method and the abundant separation and purification of polyethylene glycol precipitation with the RNA macromole.
After above-mentioned separation, purification and artificial degraded, wash this precipitation with 70% ethanol, the centrifugal back of reuse same procedure collecting precipitation is deposited in-20 ℃ preservation is standby down what obtain.
The ribonucleic acid degraded segment of the present invention that obtains through above-mentioned separation, purification with after manually degrading is a series of RNA molecules that differ in size, and their few nucleotide weight range is between 10～300, and molecular weight is 2 * 10
2～6 * 10
4Between, their complex is white or buff powder, records its purity greater than 98% through electrophoresis in conjunction with spectrophotography, soluble in water, normal saline is more stable, needs cryopreservation.
Another object of the present invention provides the application of a kind of above-mentioned ribonucleic acid retrogradation snippet compound in the preparation of treatment multigenic disease medicine.This purpose of the present invention is achieved through the following technical solutions:
Above-mentioned ribonucleic acid retrogradation snippet compound is prepared into injection according to conventional method.
Described injection is preferably water type injection or injectable sterile powder.
The conventional method of described preparation injection can be that the ribonucleic acid retrogradation snippet compound of the present invention that degraded obtains is dissolved in the normal saline of 50 times of volumes, makes water type injection; Perhaps again injectable sterile powder is made in described water type injection lyophilization.
Described multigenic disease is diseases such as hepatocarcinoma or sarcoma.
The using method of the injection of application process preparation of the present invention is: before being used for the human injection, dosage standard according to the 4mg/kg body weight, with normal saline the above-mentioned injection for preparing is suitably dissolved or dilutes, will dissolve or dilute good injection then and carry out intravenous injection; When being used for the animal body intravenous injection, the dosage standard is 10 times when being used for human body.
At present, academia thinks that micromolecular nucleic acid fragment mainly contains following two aspects to the treatment mechanism of multigenic disease: micromolecular ribonucleic acid segment can be disturbed the synthetic of paraprotein matter, and promptly micromolecule nucleic acid disturbs; Micromolecular ribonucleic acid segment can stop the cancerous cell diffusion.The inventor thinks that except that above-mentioned treatment mechanism, micromolecular nucleic acid fragment also is the treatment mechanism of multigenic disease: the distortion of lesion nucleic acid molecules or group can be corrected, repair to the normal nucleic acid fragment of external source from molecular level.
RNA retrogradation snippet compound of the present invention is the complex of a series of RNA segments compositions that differ in size that the RNA macromole forms after artificial degraded.Through described artificial biodegrading process, the structure fragment of the different sizes that are hidden in the nucleic acid molecule inside configuration is originally come out.Based on above-mentioned three kinds of treatment mechanism,, can realize treatment widely to multiple multigenic disease by the complex that these a series of nucleic acid fragments are formed.
The ribonucleic acid that is used for the treatment of multigenic disease at present in the prior art all is macromolecular substances basically, and ribonucleic acid retrogradation snippet compound of the present invention is a large amount of micromolecule segments compositions of ribonucleic acid macromole through obtaining after manually degrading; Ribonucleic acid segment of the present invention is extracted from natural animal tissue but not therefore chemosynthesis is single stranded RNA.
The ribonucleic acid degraded segment of the present invention that obtains by technique scheme is suppressing to have remarkable result aspect the advancings of disease such as hepatocarcinoma, sarcoma, has following zoopery to be card:
Test 1. ribonucleic acid retrogradation snippet compounds of the present invention to mouse bearing liver cancer H
22The influence of growth
Materials and methods:
Laboratory sample: the ribonucleic acid retrogradation snippet compound of the embodiment of the invention 1 preparation
Laboratory animal: healthy ICR mice, female, body weight 20-22g, II level cleaning level, economizing animal housing of natural drug pharmacology key lab by unming Medical College provides.
Experiment tumor kind: mouse bearing liver cancer H
22, draw from Shanghai Pharmaceutical Inst., Chinese Academy of Sciences
Experimental technique:
Well-grown tumor cell normal saline furnishing 6.5 * 10 after will inoculating 7 days
6The cell suspension of/mL concentration, it is subcutaneous to be inoculated in laboratory animal right side armpit, and 0.2mL/ is only.Inoculate and be divided into 5 groups at random after 24 hours, be respectively negative control group (A), positive controls (B), the nucleic acid molecule matched group (C) of not degrading, low dosage experimental group (D) and high dose experimental group (E), every group 8, respectively by the tail vein injection administration, wherein the A group is injected the normal saline of 0.1mL/10g body weight, B group injection cisplatin (DDP, Gejiu, Yunnan Province bio-pharmaceuticals factory, lot number 20010501) 1mg/kg body weight, the undegradable ribonucleic acid 20mg/kg body weight of C group injection, D group and the above-mentioned laboratory sample of E group injection, dosage is respectively 20mg/kg body weight and 40mg/kg.
Pressed above-mentioned dosage regimen successive administration 10 days, drug withdrawal was put to death animal after 1 day, and it is heavy with tumor to weigh respectively, calculated the suppression ratio (tumour inhibiting rate) that each average tumor of organizing weighed and calculated as follows tumor growth:
Experimental result: see Table 1
Table 1. ribonucleic acid retrogradation snippet compound of the present invention is to mouse bearing liver cancer H
22The inhibitory action of growth (X ± S)
| Group | Dosage (mg/kg) | Body weight (g) | Tumor heavy (g) | Tumour inhibiting rate (%) | |
| Before the administration | After the administration | ||||
| A | -- | 20.12±1.60 | 24.88±1.62 | 1.05±0.25 | -- |
| B | 1 | 21.30±1.95 | 24.00±1.77 | 0.27±0.19 | 74.19 |
| C | 20 | 21.46±0.33 | 25.37±3.70 | 1.10±0.60 | 20.00 |
| D | 20 | 20.05±2.04 | 23.93±1.78 | 0.42±0.13 | 59.41 |
| E | 40 | 20.62±2.22 | 24.11±2.28 | 0.36±0.15 | 65.99 |
By above-mentioned experimental result as seen, ribonucleic acid retrogradation snippet compound of the present invention is to mouse bearing liver cancer H
22The inhibitory action of growth is compared with negative control group has highly significant statistically, and the dose-effect result is obvious; And can see, significantly strengthen than the inhibitory action of undegradable ribonucleic acid macromole through the ribonucleic acid retrogradation snippet compound after the artificial degraded hepatocarcinoma.
Test 2. ribonucleic acid retrogradation snippet compounds of the present invention to mouse transplanted sarcoma S
180The influence of growth
Laboratory sample, laboratory animal, experimental technique are all identical with experiment 1, just the nucleic acid molecule matched group of not degrading is not established in experiment, laboratory animal is divided into 4 groups: negative control group (A), positive controls (B), low dosage experimental group (C) and high dose experimental group (D), and also employed tumor kind is mouse transplanted sarcoma S
180
Experimental result: see Table 2.
Table 2. ribonucleic acid retrogradation snippet compound of the present invention is to mouse transplanted sarcoma S
180The inhibitory action of growth (X ± S)
| Group | Dosage (mg/kg) | Body weight (g) | Tumor heavy (g) | Tumour inhibiting rate (%) | |
| Before the administration | After the administration | ||||
| A | -- | 20.01±2.36 | 22.96±2.43 | 1.03±0.18 | -- |
| B | 1 | 19.76±1.24 | 21.18±1.98 | 0.53±0.12 | 51.08 |
| C | 20 | 20.42±1.69 | 22.98±1.88 | 0.49±0.18 | 52.68 |
| D | 40 | 19.37±0.81 | 22.11±1.47 | 0.38±0.16 | 62.59 |
By above-mentioned experimental result as seen, ribonucleic acid retrogradation snippet compound of the present invention is to mouse transplanted sarcoma S
180The inhibitory action of growth is compared with negative control group has highly significant statistically, and the dose-effect result is obvious.
Obtain through acute toxicity testing in addition, ribonucleic acid retrogradation snippet compound MID＞266.0mg/kg of the present invention, visible ribonucleic acid retrogradation snippet compound of the present invention has the advantage of high-efficiency low-toxicity.
The specific embodiment
Embodiment 1.
1. 15 centimeters long tire pigs of left and right sides body are cleaned, get its liver, kidney and heart, shred behind the flush away blood, the reuse cutting machine is pulverized, the sucrose that adds the 0.2M of its 10 times of volumes, add again NaCl to its final concentration be 0.14M, use milling treatment of colloid, then centrifugal 20 minutes of 5 ℃ of speed with 5000 rev/mins, get the 0.01M Tris solution that the gained supernatant is dissolved in its 10 times of volumes, keep pH 6.0, add isopyknic extracting solution therein, this extracting solution is the phenol that the 0.01M Tris solution equilibria of pH 6.0 is crossed: chloroform: isoamyl alcohol was by 1: 1: 1/24 blended mixed solution of volume ratio, and vibration is extracted after 10 minutes and got supernatant in centrifugal 20 minutes 5 ℃ of speed with 6000 rev/mins then;
2. with the supernatant of extracting solution extraction step 1 gained of above-mentioned steps 1, and, get supernatant centrifugal 20 minutes of 5 ℃ of speed with 6000 rev/mins;
3. the supernatant that step 2 is obtained equal-volume chloroform extraction, and centrifugal 20 minutes of 5 ℃ of speed with 6000 rev/mins is got reuse equal-volume chloroform extraction and centrifugal with condition behind the supernatant, gets supernatant;
4. add the ethanol of 2.5 times of volumes 95% and the 3M sodium acetate of 1/10 volume in the supernatant that step 3 obtains, precipitation is spent the night, and centrifugal 20 minutes of 5 ℃ of speed with 6000 rev/mins, collecting precipitation also was dissolved in the 0.01M Tris solution of pH6.0 then;
5. added isopyknic 10% PEG 4000 precipitations 40 minutes in the solution that step 4 obtains, 5 ℃ of speed with 6000 rev/mins is centrifugal 20 minutes then, and collecting precipitation is dissolved in the 0.01M Tris solution of pH6.0;
6. in the solution that step 5 obtains, add equal-volume 0.2N NaOH, regulate pH to 6.0 with 36% acetic acid at 0 ℃ of placing response after 60 minutes, 5 ℃ of speed with 6000 rev/mins is centrifugal 20 minutes then, collecting precipitation, ethanol with 70% is washed, reuse same procedure centrifugal collecting precipitation promptly obtains RNA retrogradation snippet compound of the present invention.
After above-mentioned RNA retrogradation snippet compound carried out agarose gel electrophoresis experiment, can confirm that wherein RNA fragment is 2 * 10
2～6 * 10
4Colour developing is all arranged in the zone between the molecular weight.
Above-mentioned gained RNA retrogradation snippet compound is white or buff powder, detects in conjunction with spectrophotography through electrophoresis, and its purity is greater than 98%, and soluble in water and normal saline is more stable, needs-20 ℃ of preservations standby.
Embodiment 2.
1. 20 centimeters long tire pigs of left and right sides body are cleaned, get its liver, kidney and heart, shred behind the flush away blood, the reuse cutting machine is pulverized, the sucrose that adds the 0.2M of its 10 times of volumes, add again NaCl to its final concentration be 0.14M, use milling treatment of colloid, then centrifugal 20 minutes of 5 ℃ of speed with 5000 rev/mins, get the 0.01M Tris solution that the gained supernatant is dissolved in its 10 times of volumes, keep pH 6.0, add isopyknic extracting solution therein, this extracting solution is the phenol that the 0.01M Tris solution equilibria of pH6.0 is crossed: chloroform: isoamyl alcohol was by 1: 1: 1/24 blended mixed solution of volume ratio, and vibration is extracted after 15 minutes and got supernatant in centrifugal 20 minutes 5 ℃ of speed with 6000 rev/mins then;
2. with the supernatant of extracting solution extraction step 1 gained of above-mentioned steps 1, and, get supernatant centrifugal 20 minutes of 5 ℃ of speed with 6000 rev/mins;
3. the supernatant that step 2 is obtained equal-volume chloroform extraction, and centrifugal 20 minutes of 5 ℃ of speed with 6000 rev/mins is got reuse equal-volume chloroform extraction and centrifugal with condition behind the supernatant, gets supernatant;
4. add the ethanol of 2.5 times of volumes 95% and the 3M sodium acetate of 1/10 volume in the extracting solution that step 3 obtains, precipitation is spent the night, and centrifugal 20 minutes of 5 ℃ of speed with 6000 rev/mins, collecting precipitation also was dissolved in the 0.01M Tris solution of pH6.0 then;
5. in the solution that step 4 obtains, add equal-volume 0.2N NaOH, 0 ℃ of placing response after 30 minutes with 36% acetic acid adjusting pH to 6.0;
6. PEG 4000 precipitations of adding isopyknic 10% in the solution that step 5 obtains are 60 minutes, 5 ℃ of speed with 6000 rev/mins is centrifugal 20 minutes then, collecting precipitation, wash with 70% ethanol then, reuse same procedure centrifugal collecting precipitation promptly obtains RNA retrogradation snippet compound of the present invention.
After above-mentioned RNA retrogradation snippet compound carried out agarose gel electrophoresis experiment, can confirm that wherein RNA fragment is 2 * 10
2～6 * 10
4Colour developing is all arranged in the zone between the molecular weight.
Gained RNA retrogradation snippet compound is white or buff powder, detects in conjunction with spectrophotography through electrophoresis, and its purity is greater than 98%, and soluble in water and normal saline is more stable, needs-20 ℃ of preservations standby.
Embodiment 3.
Application Example
The ribonucleic acid retrogradation snippet compound of embodiment 1 preparation of 1ml is dissolved in the normal saline of 50ml, promptly is prepared into the storing solution of ribonucleic acid retrogradation snippet compound injection of the present invention, the concentration of this storing solution of reuse spectrophotometry.
When human body uses, after according to the dosage standard of 4mg/kg above-mentioned storing solution suitably being diluted with normal saline, pass through intravenous administration.
Embodiment 4.
Application Example
The ribonucleic acid retrogradation snippet compound of embodiment 2 preparation of 1.5ml is dissolved in the normal saline, make final concentration be 4mg/ml then with conventional method with the solution lyophilization for preparing, promptly obtain the injectable sterile powder of ribonucleic acid retrogradation snippet compound of the present invention.
When human body uses, according to the dosage standard of 4mg/kg with above-mentioned sterilized powder with physiological saline solution after, pass through intravenous administration.
Claims (6)
1. ribonucleic acid degradation fragment complex is characterized in that: the artificial degradation fragment of the ribonucleic acid that it is gone out by separation and purification in the haslet is formed; The method of described separation and purification is phenol extraction-sedimentation method and polyethylene glycol precipitation; The method of described artificial degraded is the alkaline degradation method, promptly adds equal-volume 0.2N NaOH in being dissolved with the buffer of ribonucleic acid, regulates pH to 6.0 after 20～60 minutes in 0 ℃ of placement; Through described artificial degraded, the segmental few nucleotide weight range of described ribonucleic acid is between 10～300, and molecular weight is 2 * 10
2～6 * 10
4Between.
2. the described ribonucleic acid degradation fragment of claim 1 complex, it is characterized in that: described pig is non-adult pig.
3. the described ribonucleic acid degradation fragment of claim 2 complex, it is characterized in that: described non-adult pig is the tire pig.
4. the described ribonucleic acid degradation fragment of claim 1 complex, it is characterized in that: described haslet is liver, kidney and the heart of pig.
5. the application of the described ribonucleic acid degradation fragment of claim 1 complex in the preparation of treatment multigenic disease medicine is characterized in that: described ribonucleic acid degradation fragment complex is prepared into injection according to conventional method; Described multigenic disease is hepatocarcinoma or sarcoma.
6. the described application of claim 5 is characterized in that: described injection is water type injection or injectable sterile powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100563612A CN101229183B (en) | 2008-01-17 | 2008-01-17 | Ribonucleic acid retrogradation snippet compound and applications thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100563612A CN101229183B (en) | 2008-01-17 | 2008-01-17 | Ribonucleic acid retrogradation snippet compound and applications thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101229183A CN101229183A (en) | 2008-07-30 |
| CN101229183B true CN101229183B (en) | 2010-11-24 |
Family
ID=39896197
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008100563612A Expired - Fee Related CN101229183B (en) | 2008-01-17 | 2008-01-17 | Ribonucleic acid retrogradation snippet compound and applications thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101229183B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012048470A1 (en) * | 2010-10-15 | 2012-04-19 | 杨俊海 | Small molecular ribonucleic acid complexes from mammals |
| CN102174513B (en) * | 2011-02-17 | 2013-09-18 | 杨俊海 | Mammal ribonucleic acid small molecular compound and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1478789A (en) * | 2003-06-19 | 2004-03-03 | 威世药业（如皋）有限公司 | Preparation method of ribonucleic acid |
| US20040110706A1 (en) * | 2000-12-20 | 2004-06-10 | Wallace Robyn Heather | Sodium-channel alpha1-subunit and their polypeptides and their treatment of generalised epilepsy with febrile seizures plus |
| CN1560068A (en) * | 2004-03-12 | 2005-01-05 | 嘉兴市嘉信生命科技有限公司 | Process for producing deoxyribonucleoside by thymus of pig, sheep or chicken duck as raw material |
| US20050113324A1 (en) * | 2003-01-15 | 2005-05-26 | Bondarev Igor E. | Modulation of line-1 reverse transcriptase |
-
2008
- 2008-01-17 CN CN2008100563612A patent/CN101229183B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040110706A1 (en) * | 2000-12-20 | 2004-06-10 | Wallace Robyn Heather | Sodium-channel alpha1-subunit and their polypeptides and their treatment of generalised epilepsy with febrile seizures plus |
| US20050113324A1 (en) * | 2003-01-15 | 2005-05-26 | Bondarev Igor E. | Modulation of line-1 reverse transcriptase |
| CN1478789A (en) * | 2003-06-19 | 2004-03-03 | 威世药业（如皋）有限公司 | Preparation method of ribonucleic acid |
| CN1560068A (en) * | 2004-03-12 | 2005-01-05 | 嘉兴市嘉信生命科技有限公司 | Process for producing deoxyribonucleoside by thymus of pig, sheep or chicken duck as raw material |
Non-Patent Citations (1)
| Title |
|---|
| CN 1560068 A,说明书第1-2页. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101229183A (en) | 2008-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101020719B (en) | Composite angelica polysaccharide and its preparation process and use | |
| CN105012271A (en) | Doxorubicin and TRAIL co-supported albumin nanoparticle targeting preparation and preparation method thereof | |
| CN1174748C (en) | New use of docetaxel for treating hepatoma | |
| CN101229183B (en) | Ribonucleic acid retrogradation snippet compound and applications thereof | |
| CN110897998B (en) | Genetic engineering polypeptide nano hydrogel simultaneously loaded with hydrophobic drug and hydrophilic drug and preparation method thereof | |
| CN1273496C (en) | Polysaccharose MF4 of mussel with enhancing immunity and anti-tumour activity | |
| CN1195529C (en) | Composition containing muscle-derived active agents | |
| US20220265697A1 (en) | ß-GLUCAN COMPOSITION AND USE THEREFOR | |
| CN102188719B (en) | Application of EB virus miR-BART3 antisense oligonucleotides in preparing medicament for treating nasopharyngeal darcinoma | |
| CN114668742A (en) | Bacteria-like nano-drug delivery system and preparation method and application thereof | |
| CN102114047B (en) | Woodlouse lyophilized powders 1 and 2 prepared by combined enzymolysis of pepsin and trypsinase and application thereof | |
| CN101229184B (en) | DNA degradation fragment compound and applications thereof | |
| CN1802172A (en) | Therapeutic composition for autoimmune conditions | |
| CN102641509B (en) | Application of Epstein barr (EB) virus miR-BART7 antisense oligonucleotide in preparing medicine capable of treating nasopharynx cancer | |
| CN115521385B (en) | Armillarisin mycelium polysaccharide, preparation method thereof and application thereof in resisting tumors | |
| CN1706376A (en) | Application of garcinolic acid in preparing medicine for treating tumor metastasis | |
| CN107595773B (en) | Peperomin E submicron emulsion for intravenous injection and application thereof | |
| CN1896100A (en) | Liver regenerated factor and its use | |
| CN101829062A (en) | Taxol slow release microballoons and preparation method thereof | |
| CN105688184B (en) | A kind of hypodermic injection situ-gel for being used to treat osteosarcoma | |
| CN1265840C (en) | Immunity coupler of containing monoclonal antibody Fab' segment of anti TV type collagenase poly glutamic acid-blemycin A5 | |
| CN102218148A (en) | Use of epstein-barr virus miR-BART1-5p antisense oligonucleotide in preparing drugs for treating nasopharyngeal carcinoma | |
| CN1557313A (en) | Leukemia and myeloma treating plant extract and natural chemical monomer | |
| CN114796202A (en) | Vitamin C and oncolytic virus combined medicine for treating cancer | |
| WO2024145901A1 (en) | Drug-co-loaded micelle, synergistic drug system thereof, preparation method therefor, and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| PB01 | Publication | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20080530 Address after: Floor 12, building 8, Longhu Industrial Zone, No. 4 Jiang Nan Road, Guangdong, Shantou Applicant after: Zhou Xi Zhang Co-applicant after: Tuobin Pharmacentical Factory, Shantou Ecomomic Special Zone Address before: Beijing city Xuanwu District South Road No. 2 Building No. 6 compound 2 unit 1107 room Applicant before: Zhou Xizhang |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20101124 Termination date: 20210117 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |